Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
Coagulation01:09

Coagulation

12.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
12.4K
Coagulation01:06

Coagulation

1.7K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.7K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.9K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

473
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
473

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural features of endogenous polyphenols in modulating oxidative stability of tiger nut (Cyperus esculentus L.) oil: Insights from Rancimat and density functional theory.

Food chemistry·2026
Same author

Delayed Arousal Response to Sleep Apnea Encodes Mortality.

medRxiv : the preprint server for health sciences·2026
Same author

SERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD<sup>+</sup> homeostasis and suppressing Sirt3 activity.

Redox biology·2026
Same author

Protocol for detecting genome-wide introgressed genes and evaluating their functional legacy.

STAR protocols·2026
Same author

A layered standards framework for integrating single-cell and spatial omics data into brain cell atlases.

bioRxiv : the preprint server for biology·2026
Same author

A Community Standard Multispecies Cell Atlas of the Basal Ganglia.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Apr 17, 2026

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.4K

[Hypercoagulable state in patients with multiple myeloma].

Zeng-Yan Liu1, Guo-Qiang Zhang2, Wen-Zheng Yu1

  • 1Department of Hematology, Affiliated Hospital of Bingzhou Medical College, Bingzhou 256603, Shandong Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|February 18, 2015
PubMed
Summary

Plasma thrombomodulin (TM), D-dimer, and fibrinogen are elevated in multiple myeloma (MM) patients, indicating a potential thrombosis risk, especially with thalidomide treatment.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Related Experiment Videos

Last Updated: Apr 17, 2026

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.4K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Chemistry

Background:

  • Multiple myeloma (MM) is a hematologic malignancy.
  • Coagulation abnormalities are common in MM patients.
  • Thrombosis is a significant complication in MM.

Purpose of the Study:

  • To measure plasma thrombomodulin (TM), D-dimer, and fibrinogen levels in MM patients.
  • To analyze the relationship between these markers and disease status.
  • To investigate the correlation between coagulation factors and myeloma cell ratio.

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) for TM detection.
  • STA automatic coagulation analyzer for D-dimer and fibrinogen.
  • Study included 45 MM patients across different stages.

Main Results:

  • Elevated plasma TM, D-dimer, and fibrinogen in MM patients compared to controls.
  • Highest D-dimer levels observed in relapsed/refractory MM.
  • TM and D-dimer levels increased with thalidomide-based chemotherapy.

Conclusions:

  • Plasma TM, D-dimer, and fibrinogen are reliable biomarkers in MM.
  • Elevated levels suggest an increased risk of thrombosis in MM.
  • Thalidomide treatment may further increase this thrombotic tendency.